Low-affinity neurotensin receptor (NTS2) signaling: Internalization- dependent activation of extracellular signal-regulated kinases 1/2

Molecular Pharmacology

Volumn 66, Issue 6, 2004, Pages 1421-1430

  Gendron, Louis ^a   Perron, Amélie ^a   Payet, Marcel Daniel ^b   Gallo Payet, Nicole ^c   Sarret, Philippe ^a   Beaudet, Alain ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; ARSENOSOBENZENE; DANSYLCADAVERINE; LEVOCABASTINE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROMEDIN N; NEUROTENSIN; NEUROTENSIN RECEPTOR;

ANIMAL CELL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM TRANSPORT; CHO CELL; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENDOCYTOSIS; ENZYME ACTIVATION; GENE OVEREXPRESSION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SPECIES DIFFERENCE;

ANIMALS; BASE SEQUENCE; CALCIUM; CHO CELLS; CRICETINAE; DNA PRIMERS; ENZYME ACTIVATION; HISTAMINE H1 ANTAGONISTS; KINETICS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROTENSIN; PIPERIDINES; RATS; RECEPTORS, NEUROTENSIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 9444237973     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.002303     Document Type: Article

References (48)

1. Barroso S, Richard P, Nicolas-Ethève D, Reversat JL, Bernassau JM, Kitabgi P, and Labbé-Jullié C (2000) Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1. J Biol Chem 275:328-336.
2. Binder EB, Kinkead B, Owens MJ, and Nemeroff CB (2001) Neurotensin and dopamine interactions. Pharmacol Rev 53:453-486.
3. Botto JM, Chabry J, Sarret P, Vincent JP, and Mazella J (1998) Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling and internalization mechanism. Biochem Biophys Res Commun 243:585-590.
4. Botto JM, Guillemare E, Vincent JP, and Mazella J (1997) Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the X. laevis oocyte expression system: agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neurosci Lett 223:193-196.
5. Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, and Caput D (1996) Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 386:91-94.
6. Claing A, Laporte SA, Caron MG, and Lefkowitz RJ (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66:61-79.
7. Dubuc I, Costentin J, Terranova JP, Baraouin MC, Soubrié P, Le Fur G, Rostène W, and Kitabgi P (1994) The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br J Pharmacol 112:352-354.
8. Dubuc I, Remande S, and Costentin J (1999a) The partial agonist properties of levocabastine in neurotensin-induced analgesia. Eur J Pharmacol 381:9-12.
9. Dubuc I, Sarret P, Labbé-Jullié C, Botto JM, Honoré E, Bourdel E, Martinez J, Costentin J, Vincent JP, Kitabgi P, et al. (1999b) Identification of the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci 19:503-510.
10. Ehlers RA, Bonnor RM, Wang X, Hellmich MR, and Evers BM (1998) Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery 124:239-246; discussion 246-247.
11. Ehlers RA, Zhang Y, Hellmich MR, and Evers BM (2000) Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 269:704-708.
12. Gendron L, Oligny JF, Payet MD, and Gallo-Payet N (2003) Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem 278:3606-3614.
13. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, et al. (1993) Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 80:65-69.
14. Hermans E and Maloteaux JM (1998) Mechanisms of regulation of neurotensin receptors. Pharmacol Ther 79:89-104.
15. Kalivas PW, Gau BA, Nemeroff CB, and Prange AJ Jr (1982) Antinociception after microinjection of neurotensin into the central amygdaloid nucleus of the rat. Brain Res 243:279-286.
16. Kinkead B and Nemeroff CB (2002) Neurotensin: an endogenous antipsychotic? Curr Opin Pharmacol 2:99-103.
17. Kitabgi P, Hervé D, Studler JM, Tramu G, Rostène W, and Tassin JP (1989) Neurotensin/dopamine interactions. Encephale 15:91-94.
18. Kitabgi P, Rostène W, Dussaillant M, Schotte A, Laduron PM, and Vincent JP (1987) Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur J Pharmacol 140:285-293.
19. Kranenburg O, Verlaan I, and Moolenaar WH (1999) Dynamin is required for the activation of mitogen-activated protein (MAP) kinase by MAP kinase kinase. J Biol Chem 274:35301-35304.
20. 3H]-SR48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol 47:1050-1056.
21. Martin GE, Bacino CB, and Papp NL (1980) Hypothermia elicited by the intracerebral microinjection of neurotensin. Peptides 1:333-339.
22. Martin S, Navarro V, Vincent JP, and Mazella J (2002a) Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 123:1135-1143.
23. Martin S, Vincent JP, and Mazella J (2002b) Recycling ability of the mouse and the human neurotensin type 2 receptors depends on a single tyrosine residue. J Cell Sci 115:165-173.
24. Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, and Vincent JP (1996) Structure, functional expression and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 16:5613-5620.
25. Mazella J, Zsürger N, Navarro V, Chabry J, Kaghad M, Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, et al. (1998) The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem 273:26273-26276.
26. Miller WE and Lefkowitz RJ (2001) Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr Opin Cell Biol 13:139-145.
27. Nemeroff CB (1986) The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 11:15-37.
28. Nouel D, Sarret P, Vincent JP, Mazella J, and Beaudet A (1999) Pharmacological, molecular and functional characterization of glial neurotensin receptors. Neuroscience 94:1189-1197.
29. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Rasmussen HH, Roigaard H, Gliemann J, Madsen P, and Moestrup SK (1997) Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 272:3599-3605.
30. Pettibone DJ, Hess JF, Hey PJ, Jacobson MA, Leviten M, Lis EV, Mallorga PJ, Pascarella DM, Snyder MA, Williams JB, et al. (2002) The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J Pharmacol Exp Ther 300:305-313.
31. Pierce KL, Maudsley S, Daaka Y, Luttrell LM, and Lefkowitz RJ (2000) Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc Natl Acad Sci USA 97:1489-1494.
32. Poinot-Chazel C, Portier M, Bouaboula M, Vita N, Pecceu F, Gully D, Monroe JG, Maffrand JP, Le Fur G, and Casellas P (1996) Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem J 320 (Pt 1):145-151.
33. Portier M, Combes T, Gully D, Maffrand JP, and Casellas P (1998) Neurotensin type 1 receptor-mediated activation of krox24, c-fos and Elk-1: preventing effect of the neurotensin antagonists SR 48692 and SR 142948. FEBS Lett 432:88-93.
34. Remaury A, Vita N, Gendreau S, Jung M, Arnone M, Poncelet M, Culouscou JM, Le Fur G, Soubrié P, Caput D, et al. (2002) Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia. Brain Res 953:63-72.
35. Richard F, Barroso S, Martinez J, Labbé-Jullié C, and Kitabgi P (2001) Agonism, inverse agonism and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol 60:1392-1398.
36. Rioux F, Quirion R, St-Pierre S, Regoli D, Jolicoeur FB, Bélanger F, and Barbeau A (1981) The hypotensive effect of centrally administered neurotensin in rats. Eur J Pharmacol 68:241-247.
37. Rostène W and Alexander MJ (1997) Neurotensin and neuroendocrine regulation. Front Neuroendocrinol 18:115-173.
38. Sarret P, Gendron L, Kilian P, Nguyen HM, Gallo-Payet N, Payet MD, and Beaudet A (2002) Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells. J Biol Chem 277:36233-36243.
39. Sarret P, Perron A, Stroh T, and Beaudet A (2003) Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J Comp Neurol 461:520-538.
40. 3H]neurotensin binding site in rat brain. Naunyn Schmiedeberg's Arch Pharmacol 333:400-405.
41. Tanaka K, Masu M, and Nakanishi S (1990) Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4:847-854.
42. Tyler BM, Jansen K, McCormick DJ, Douglas CL, Boules M, Stewart JA, Zhao L, Lacy B, Cusack B, Fauq A, et al. (1999) Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci USA 96:7053-7058.
43. Vincent JP (1995) Neurotensin receptors: binding properties, transduction pathways and structure. Cell Mol Neurobiol 15:501-512.
44. Vincent JP, Mazella J, and Kitabgi P (1999) Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20:302-309.
45. Vita N, Laurent P, Lefort S, Chalon P, Dumont X, Kaghad M, Gully D, Le Fur G, Ferrara P, and Caput D (1993) Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 317:139-142.
46. Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A, Thurneyssen O, Garcia S, Poinot-Chazel C, Casellas P, et al. (1998) Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol 360:265-272.
47. Yamada M, Lombet A, Forgez P, and Rostène W (1998) Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Life Sci 62:PL375-PL380.
48. Yamauchi R, Sonoda S, Jinsmaa Y, and Yoshikawa M (2003) Antinociception induced by beta-lactotensin, a neurotensin agonist peptide derived from beta-lactoglobulin, is mediated by NT2 and D1 receptors. Life Sci 73:1917-1923.